皇冠体育寻求亚洲战略合作伙伴,皇冠代理招募中,皇冠平台开放会员注册、充值、提现、电脑版下载、APP下载。

首页社会正文

新2平台出租(www.hg108.vip):No major delays in companies' IPO plans in 2022

admin2022-08-256

新2平台出租www.hg108.vip)是皇冠(正网)接入菜宝钱包的TRC20-USDT支付系统,为皇冠代理提供专业的网上运营管理系统。系统实现注册、充值、提现、客服等全自动化功能。采用的USDT匿名支付、阅后即焚的IM客服系统,让皇冠代理的运营更轻松更安全。

The Star

KUALA LUMPUR: Bursa Malaysia Bhd does not foresee any major delays in companies’ listing plans in 2022 despite a risk-off environment sparked by a hawkish United States Federal Reserve (Fed) and external headwinds like the Ukraine-Russia war.

Instead, it anticipated the local bourse to see 37 initial public offerings (IPOs) in 2022 against 30 in 2021, primarily driven by a higher number of listings on the ACE Market following the reopening of the economy.

"Unless an IPO is large enough to warrant an international offering, we do not foresee any major delays in companies’ listing plans, as there is ample liquidity in our market to support purely domestic offerings," Bursa Malaysia told Bernama recently.

The exchange operator said from Jan 1-July 13, 2022, the local bourse saw 20 new listings, raising about RM2.3 billion.

"The additional market capitalisation contributed by the 20 companies listed is approximately RM7.3 billion (up to July 13, 2022), and the IPO pipeline for the rest of the year remains strong," it said.

Based on the number of IPOs approved and awaiting their listing and the number of exposure draft prospectuses on both Bursa Malaysia and the Securities Commission Malaysia's (SC) websites, at least five more listings are expected to take place by year-end.

Yesterday, UMediC Group Bhd (UMC) made a strong debut on the ACE Market at 50 sen per share -- a 56.25 per cent premium from its IPO price of 32 sen.

,

澳洲幸运5开奖网www.a55555.net)是澳洲幸运5彩票官方网站,开放澳洲幸运5彩票会员开户、澳洲幸运5彩票代理开户、澳洲幸运5彩票线上投注、澳洲幸运5实时开奖等服务的平台。

,

The medical device manufacturer’s counter closed at 44 sen, resulting in a market capitalisation of RM164.52 million.

Moving forward, Bursa Malaysia believes that the domestic investors' appetite for IPOs would remain strong for the rest of the year as demonstrated by the level of oversubscription for most IPOs.

It said businesses are expected to rebound on pent-up demand following the pandemic, and the reopening of borders will encourage spending.

"Hence, we believe the outlook for IPOs remains encouraging, as the equity capital market provides companies with access to funds for growth and recovery from the impact brought about by the COVID-19 pandemic.

"We are optimistic that the vibrancy and momentum of new IPOs on Bursa Malaysia will remain throughout 2022, particularly in the key promoted areas of technology, consumer, healthcare, halal and/or environmental, social and corporate governance (ESG)-compliant businesses," it added.

Like most of its emerging-market peers, Malaysia has been suffering from a persistent sell-off in its equity market since the Fed made its third interest rate hike in June this year, raising it by 75 basis points (bps) -- the most aggressive hike since 1994.

Year-to-date, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) has dropped 6.62 per cent to close at 1,463.69 on July 26, 2022.

网友评论